Ultragenyx Pharmaceutical (RARE)
(Real Time Quote from BATS)
$41.79 USD
-0.17 (-0.41%)
Updated May 8, 2024 10:40 AM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Ultragenyx Pharmaceutical Inc. [RARE]
Reports for Purchase
Showing records 21 - 40 ( 325 total )
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
With Major Fireworks Shot Off, 3Q23 Update Largely As Anticipated
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Commercial Preview: Some Fireworks Ahead, But Prereleases Steal Thunder
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Analyst Event Offers Closer Pipeline Look; In-Line Update For 2Q23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
UX701 Pivotal Cyprus2+ Trial For Wilson Disease Advances Into Higher Dose; Initial Data Expected in 1H24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Commercial Biotech Preview: Could 2Q23 Reporting Help Restart a Rally?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
As Setrusumab Advances, Assigning Credit In Our Estimates
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department